local_hospital

Unidade Local De Saude De Lisboa Ocidental E.P.E.

Address
lock Available on a paid plan

Cardiovascular Research

At Unidade Local De Saude De Lisboa Ocidental E.P.E., clinical trials in cardiovascular diseases focus on major conditions such as atrial fibrillation, heart failure, hypertension, and broader atherosclerotic cardiovascular disease. The studies are designed to test new treatment options and measure whether they can reduce serious heart- and stroke-related events.

  • Prevention of stroke, heart attack, and other major cardiovascular events
  • Management of established vascular disease and high cardiovascular risk
  • Evaluation of therapies for heart failure, cardiomyopathy, and lipid-related risk

This work reflects a strong interest in improving long-term outcomes for people with complex cardiovascular conditions.

Kidney Disease and Nephrology

The Serviço de Nefrologia is actively involved in studies across nutritional and metabolic diseases and reproductive and urinary physiological phenomena, with a strong emphasis on chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis, and autosomal dominant polycystic kidney disease. These trials aim to slow kidney decline, reduce proteinuria, and improve kidney-related outcomes.

  • Testing new approaches for proteinuria and kidney function preservation
  • Studying progressive kidney diseases and inherited renal disorders
  • Assessing therapies intended to delay worsening kidney disease

The site’s nephrology research also includes patients with advanced kidney disease and transplant-related complications, showing broad clinical engagement in renal care.

Immune-Mediated and Inflammatory Conditions

Several trials at this hospital/clinic explore immune system diseases such as lupus nephritis and other inflammatory kidney disorders. The research is centered on evaluating whether targeted therapies can better control immune-driven damage and improve renal response.

  • Immune-related kidney inflammation and autoimmune renal disease
  • Measures of proteinuria and renal response in active disease
  • Safety and effectiveness of newer immune-targeted treatments

These studies are important for patients whose kidney disease is linked to abnormal immune activity and persistent inflammation.

Transplantation and Advanced Renal Care

Research at Unidade Local De Saude De Lisboa Ocidental E.P.E. also addresses outcomes after kidney transplantation, including delayed graft function and other high-risk post-transplant challenges. The goal is to improve recovery after transplant and support better function of the donated kidney.

  • Reducing complications after deceased-donor kidney transplantation
  • Improving early graft recovery and dialysis-free outcomes
  • Evaluating therapies for transplant-related kidney injury

This area complements the site’s broader nephrology program by focusing on recovery, safety, and better long-term transplant success.

Metabolic and Cardiometabolic Risk

Another important part of the trial portfolio involves nutritional and metabolic diseases linked to kidney and heart health, including studies in obesity, elevated lipoprotein(a), and other cardiometabolic risk factors. These trials are designed to see whether new therapies can lower risk and protect both the heart and kidneys.

  • Cardiometabolic risk reduction in people with kidney disease or vascular disease
  • Evaluation of treatments for inflammation, lipids, and blood pressure control
  • Prevention of future cardiovascular and renal complications

The research combines prevention and treatment goals, linking metabolic health with cardiovascular and renal protection.

Pediatric and Specialized Cardiovascular-Kidney Studies

The site also contributes to selected studies in children and other specialized populations, including pediatric pulmonary arterial hypertension and pediatric left ventricular systolic dysfunction. These trials focus on whether treatments are safe and effective in younger patients with serious heart or kidney-related conditions.

  • Children with pulmonary vascular disease
  • Pediatric heart failure and ventricular dysfunction
  • Long-term safety and symptom improvement in specialized groups

By participating in these studies, the center supports research that extends beyond adult nephrology into carefully selected pediatric and cardiopulmonary conditions.

Site Overview

assignment
105
connected trials
corporate_fare
51
sponsors
science
165
IMPs

Activity Indicator

Last 6 months

6
Trials started
-25% vs previous period.
8
Trials started 6–12 months ago
105
Total trials linked
Highly Active
trending_downDeclining-25%
2
1
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 17 therapeutic areas and 15 of 165 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 163 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
47
Sponsors (total)
51
Active sponsors
31

Sponsor Network

Top 31 by active trials.

lock +30 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +17 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 84 other sites in Portugal

description
Trial volume
105
Outperforms 88% of sites
public
Therapeutic diversity
17areas
Outperforms 92% of sites
groups
Sponsor diversity
51sponsors
Outperforms 88% of sites

Therapeutic Area Benchmark — Portugal

Select a therapeutic area to compare against other sites in Portugal.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Portugal

Market Share

Country: Portugal

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Unidade Local De Saude De Lisboa Ocidental E.P.E.

lock Showing 1 of 105 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 165 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab6Unknown2020-03-172025-11-10

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.